Boothbay Fund Management’s Celldex Therapeutics CLDX Stock Holding History

Boothbay Fund Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.24M	Hold	33,300	–	–	0.02%	972
2026 Q1	$1.06M	Buy	+33,300	New	+$908K	0.01%	919
2025 Q1	–	Sell	-60,900	Closed	-$1.54M	–	1448
2024 Q4	$1.54M	Sell	60,900 -29,300	-32%	-$796K	0.04%	514
2024 Q3	$3.07M	Buy	+90,200	New	+$3.44M	0.07%	388
2023 Q4	–	Sell	-19,800	Closed	-$545K	–	1688
2023 Q3	$545K	Buy	+19,800	New	+$621K	0.01%	996
2023 Q2	–	Sell	-22,500	Closed	-$810K	–	1882
2023 Q1	$810K	Buy	+22,500	New	+$971K	0.02%	1083
2022 Q3	–	Sell	-87,500	Closed	-$2.36M	–	2277
2022 Q2	$2.36M	Buy	87,500 +21,800	+33%	+$633K	0.06%	483
2022 Q1	$2.24M	Buy	65,700 +18,700	+40%	+$598K	0.05%	535
2021 Q4	$1.82M	Sell	47,000 -5,200	-10%	-$227K	0.04%	511
2021 Q3	$2.82M	Buy	+52,200	New	+$2.45M	0.08%	325
2018 Q2	–	Sell	-76	Closed	-$264K	–	758
2018 Q1	$264K	Buy	+76	New	+$2.94K	0.03%	522

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Boothbay Fund Management's CLDX Position: Q2 2026 in Review

Boothbay Fund Management increased its Celldex Therapeutics (CLDX) stake by 3.8% in Q2 2026, buying an estimated $165K and bringing the position to 140,064 shares worth $5.21M. The position accounts for 0.07% of the portfolio, ranked #339.

Boothbay Fund Management first reported a position in CLDX in Q2 2020 and has held it in 14 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Boothbay Fund Management held 140,064 shares of Celldex Therapeutics worth $5.21M as of Q2 2026.
Boothbay Fund Management bought 5,119 Celldex Therapeutics shares in Q2 2026, an estimated $165K.
Celldex Therapeutics made up 0.07% of Boothbay Fund Management's portfolio in Q2 2026, its #339 holding.
Boothbay Fund Management first reported a position in Celldex Therapeutics in Q2 2020 and has held it in 14 quarters since.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.